The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Meng, Jieru ^a   Majidi, Mourad ^a   Fang, Bingliang ^a   Ji, Lin ^a   Bekele, B Nebiyou ^a   Minna, John D ^b   Roth, Jack A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; NANOPARTICLE; PLASMID DNA; PROTEIN KINASE B INHIBITOR; PROTEIN KINASE LKB1; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN; TUSC2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; MOUSE MODEL; NONHUMAN; SIGNAL TRANSDUCTION; TRANSIENT EXPRESSION; TUMOR CELL; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; TUSC2 GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LUNG NEOPLASMS; MICE; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; TUMOR STEM CELL ASSAY; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885770153     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077067     Document Type: Article

References (30)

1. Lerman MI, Minna JD, (2000) The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 60(21): 6116-6133.
2. Prudkin L, Behrens C, Liu DD, Zhou X, Ozburn NC, et al. (2008) Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res 14(1): 41-47.
3. Li G, Kawashima H, Ji L, Ogose A, Ariizumi T, et al. (2011) Frequent absence of tumor suppressor FUS1 protein expression in human bone and soft tissue sarcomas. Anticancer Res 31(1): 11-21.
4. Ji L, Nishizaki M, Gao B, Burbee D, Kondo M, et al. (2002) Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res 62(9): 2715-2720.
5. Gopalan B, Ito I, Branch CD, Stephens C, Roth JA, et al. (2004) Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 3(6): 647-657.
6. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, et al. (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11(11): 733-739.
7. Goff LW, Benson AB 3rd, LoRusso PM, Tan AR, Berlin JD, et al. (2012) Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. Invest New Drugs 30(1): 290-298.
8. Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, et al. (2007) Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 67(2): 709-717.
9. Hesson LB, Cooper WN, Latif F, (2007) Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 26(52): 7283-7301.
10. Lin J, Sun T, Ji L, Deng W, Roth J, et al. (2007) Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26(49): 6989-6996.
11. Ji L, Roth JA, (2008) Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 3(4): 327-330.
12. Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, et al. (2009) Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer 8: 91.
13. Seufferlein T, Rozengurt E, (1996) Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res 56(17): 3895-3897.
14. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63(6): 1270-1279.
15. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, et al. (2011) First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35): 4688-4695.
16. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, et al. (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7(5): 1459-1465.
17. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, et al. (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19(13): 3267-3279.
18. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139.
19. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676): 1497-1500.
20. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36): 13306-13311.
21. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1): 21-35.
22. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, et al. (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20(42): 6073-6083.
23. Bortul R, Tazzari PL, Cappellini A, Tabellini G, Billi AM, et al. (2003) Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) up-regulation. Leukemia 17(2): 379-389.
24. Meng J, Peng H, Dai B, Guo W, Wang L, et al. (2009) High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther 8(21): 2073-2080.
25. Aoki M, Blazek E, Vogt PK, (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98(1): 136-141.
26. Shackelford DB, Shaw RJ, (2009) The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9(8): 563-575.
27. Shah U, Sharpless NE, Hayes DN, (2008) LKB1 and lung cancer: more than the usual suspects. Cancer Res 68(10): 3562-3565.
28. King TD, Song L, Jope RS, (2006) AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 71(11): 1637-1647.
29. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, et al. (2004) Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 3(4): 465-472.
30. Liang X, Wang P, Gao Q, Xiang T, Tao X, (2010) Endogenous LKB1 knockdown accelerates G(1)/S transition through p53 and p16 pathways. Cancer Biol Ther 9(2): 156-160.